Benzinga
28 Sept 2026, 17:38 UTC · 2h ago
Verdict
Headline takes no side. We score ABBV +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
The FDA approved AbbVie's Juvmo (tavapadon) tablets on Friday as a treatment for adults with Parkinson's disease.
NewFDA approval happened 'On Friday' relative to Sept 28
So whatThis is the first selective D1/D5 receptor agonist approved, providing a new competitive moat for the company's neurology pipeline.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
AbbVie management believes its Parkinson's portfolio, including Juvmo, Vyalev, and Duopa, could generate at least $5 billion in peak sales.
Priced inanalysis of FDA approval results
More positive than 79% of claims this week
William Blair estimates Juvmo sales of $1.4 billion by 2040, with a list price of $58,800 annually per patient.
NewWilliam Blair note written 'on Monday'
So whatThe high price point suggests strong per-patient margins, though it may invite pricing scrutiny or slower adoption.
More positive than 66% of claims this week
Broad Medicare coverage for Juvmo is unlikely until 2028, with projected sales of only $8 million in 2026 and $70 million in 2027.
NewWilliam Blair note written 'on Monday'
So whatSince Medicare is projected to be 80% of the channel mix, the 2026-2027 revenue will be negligible relative to the total $5B franchise goal.
More negative than 69% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
FDA approval of Juvmo for Parkinson's disease is seen as a significant long-term growth driver with potential billion-dollar sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+1.0%
Price agrees with the score
$267.03 vs $264.34 close before publication (Sep 25) · not market-adjusted
ABBV chart →
